Boehringer and Lilly's combo diabetes drug Jentadueto gains EU approval

Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto, which combines the DPP-4 inhibitor linagliptin and metformin in a single tablet, which the coma]panes say will provide a new, single-tablet treatment option, taken twice-daily, for adults with type 2 diabetes.

The approval decision follows a recent European Medicines advisory committee backing for the combination drug, as well as approval from the US Food and Drug Administration (The Pharma Letters February 1 and May 28).

Simplified dosing regimen